Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI ® (sparsentan) to reduce proteinuria in adult and pediatric patients ...

Full FDA approval establishes sparsentan as the first approved therapy for FSGS, addressing a longstanding reliance on off-label immunosuppression and chronic steroids with substantial toxicity ...

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failureLigand is entitled to a 9% ...

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...

From a negative phase 3 readout and a seemingly tightening regulatory climate to a grueling three-month review extension, the path for Travere Therapeutics in its first-in-disease bid was anything but ...

With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s landmark approval for Filspari in focal segmental glomerulosclerosis (FSGS).

FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI expands total addressable ...

JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (LGND) today announced that its partner Travere Therapeutics, Inc. (TVTX) has received approval from the U.S. Food ...